Researcher Profile

Researcher Profile

Diane Hershock, MD, PhD

Diane Hershock, MD, PhD

Associate Professor, Department of Medicine
Division of Hematology and Oncology
Scientific Program:Next-Generation Therapies
Disease Teams:
Head and Neck Cancer
Melanoma and Skin Cancer
dmh58@psu.edu

Research Interests

  • Radiotherapy
  • Blood Platelets
  • Therapeutics
  • Head and Neck Neoplasms
  • Neoplasms
  • Fibrinogen
  • Survival
  • Squamous Cell Carcinoma of Head and Neck
  • Drug Therapy
  • Organ Preservation
  • Radiation Oncology
  • Chymotrypsin

Clinical Trials

Exercise in All ChemoTherapy (EnACT)
A Phase II Study of REGN2810, a Fully Human Monoclonal Antibody to Programmed Death-1, in Patients with Advanced Basal Cell Carcinoma who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy or were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy
Development and Validation of a Gene Expression Assay to Predict the Risk of Recurrent Disease in Cutaneous Squamous Cell Carcinoma
Randomized Phase II/III Trial of Radiotherapy with Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy with Concurrent Cetuximab in Patients with Locoregionally Advanced Head and Neck Cancer with a Contraindication to Cisplatin
STAMP: Surgically Treated Adjuvant Merkel cell carcinoma with Pembrolizumab, a Phase III Trial

Recent Publications

2016

Nijenhuis, CM, Hellriegel, E, Beijnen, JH, Hershock, D, Huitema, ADR, Lucas, L, Mergui-Roelvink, M, Munteanu, M, Rabinovich-Guilatt, L, Robertson, P, Rosing, H, Spiegelstein, O & Schellens, JHM 2016, 'Pharmacokinetics and excretion of 14C-omacetaxine in patients with advanced solid tumors', Investigational New Drugs, vol. 34, no. 5, pp. 565-574. https://doi.org/10.1007/s10637-016-0360-9

Clinical Trials Search


Children (age < 18 years)
Adults (age >= 18 years)